Bicara Therapeutics (BCAX) Insider Option Exercise and Sale Notice

Rhea-AI Filing Summary

Bicara Therapeutics, Inc. (BCAX) filed a Form 144 notice reporting a proposed sale of 18,244 common shares through UBS Financial Services with an aggregate market value of $328,392.00. The filing states the shares were acquired and are to be sold on 10/07/2025 following an exercise of stock options, with payment in cash.

The notice also discloses a prior sale by the same person: 6,514 shares sold on 10/06/2025 for gross proceeds of $118,356.12. The filer certifies no undisclosed material adverse information and acknowledges Rule 10b5-1/insider-trading attestation language on the form.

Insights

Securities Compliance Analyst

TL;DR: A standard Form 144 notice for option exercise sales and a nearby prior sale.

The filing documents a proposed brokered sale of 18,244 common shares on 10/07/2025 after an exercise of stock options, with an aggregate market value of $328,392.00. It also records a prior sale of 6,514 shares on 10/06/2025 for $118,356.12.

Key compliance considerations include the brokered execution via UBS Financial Services, the seller's Rule 144 representation about material nonpublic information, and the proximity of transactions; these items are typically reviewed for adherence to holding periods and aggregation rules. Monitor any subsequent filings or plan adoption dates if a Rule 10b5-1 plan is later asserted.

Insider Transaction Analyst

TL;DR: Insider exercised options and intends to sell shares; recent sale activity is disclosed.

The table shows acquisition and sale on the same date (10/07/2025) via option exercise for 18,244 shares, paid in cash, implying immediate disposition post-exercise. A separate sale of 6,514 shares occurred on 10/06/2025.

Investors typically note timing and amounts: combined recent disposition equals 24,758 shares and gross proceeds of $446,748.12. Watch for additional Forms 4/144 filings that clarify whether these sales are routine option exercises or part of a scheduled plan; such filings within days can affect short-term share supply.

FAQ

What did BCAX report on Form 144?

BCAX reported a proposed sale of 18,244 common shares via UBS on 10/07/2025 with aggregate market value $328,392.00 and a prior sale of 6,514 shares on 10/06/2025 for $118,356.12.

Why were the 18,244 BCAX shares acquired and sold?

The filing states the 18,244 shares were acquired on 10/07/2025 by exercise of stock options and the payment method for the sale is listed as cash.

Who is the broker handling the BCAX sale?

The broker named is UBS Financial Services, Inc. with an address at 11 Madison Ave, New York, NY.

Did the filer assert no material nonpublic information?

Yes. The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed, per the Form 144 attestation.

How much total recent BCAX stock was disclosed as sold or to be sold?

The filings disclose 6,514 shares sold on 10/06/2025 and 18,244 shares proposed for sale on 10/07/2025, totaling 24,758 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	18244	328392.00	54562841	10/07/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/07/2025	Exercise of stock options	Issuer			18244	10/07/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116	Common	10/06/2025	6514	118356.12

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)